829
Participants
Start Date
June 23, 2016
Primary Completion Date
July 5, 2023
Study Completion Date
July 5, 2023
feladilimab (GSK3359609)
GSK3174998
Pembrolizumab
Docetaxel
Pemetrexed
Paclitaxel plus Carboplatin
Gemcitabine plus Carboplatin
Fluorouracil (5-FU) plus carboplatin or cisplatin
Dostarlimab
Cobolimab
Bintrafusp alfa
GSK Investigational Site, Melbourne
GSK Investigational Site, Heidelberg
GSK Investigational Site, Nedlands
GSK Investigational Site, New York
GSK Investigational Site, New York
GSK Investigational Site, Philadelphia
GSK Investigational Site, Madrid
GSK Investigational Site, Mága
GSK Investigational Site, Bordeaux
GSK Investigational Site, Sarasota
GSK Investigational Site, Nashville
GSK Investigational Site, Seville
GSK Investigational Site, Siena
GSK Investigational Site, Lyon
GSK Investigational Site, Oklahoma City
GSK Investigational Site, Paris
GSK Investigational Site, Los Angeles
GSK Investigational Site, Duarte
GSK Investigational Site, Villejuif
GSK Investigational Site, Shnghai
GSK Investigational Site, Nashville
GSK Investigational Site, Toronto
GSK Investigational Site, Chiba
GSK Investigational Site, Osaka
GSK Investigational Site, Tokyo
GSK Investigational Site, Amsterdam
GSK Investigational Site, Barcelona
GSK Investigational Site, Barcelona
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
GlaxoSmithKline
INDUSTRY